TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: changes in absolute numbers and density of immunocompetent cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: inflammatory cytokines expression pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events of special interest (respiratory)
Endpoint domain: Adverse events/effects
Primary endpoint: incremental cost per mm reduction in SBP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incremental cost per mm reduction in DBP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients in NYHA class I, II, III, or IV
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of suitable subjects
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in apnea-hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Concentration of red blood cell folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of serum folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of unmetabolized folic acid and other folate forms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evaluators Global Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ALD value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ICU Team Members (Learners) Who Received Education
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Learner Attitudes Regarding Education (Mean Scores on Relevant Survey Questions)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Any local or distant relapse of breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Any second malignancy
Endpoint domain: Mortality/survival
Primary endpoint: Any death irrespective of its cause
Endpoint domain: Mortality/survival
Primary endpoint: Posterior fossa intracranial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical status of patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Marijuana addiction severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana withdrawal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: E-Max liner wear rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Rate of Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDA production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic sensitivity of 18F-FDG PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of absence from school due to IBD
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants With Hospital Readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change From Baseline in Social Interaction Anxiety Scale (SIAS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change From Baseline in Social Phobia Scale (SPS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Liebowitz Social Anxiety Scale (LSAS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change of skin moisture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of skin elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of skin wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of skin collagen density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of subjects with treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Desaturation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with anti-lixisenatide antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Local Injection Site Reaction by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Systemic Adverse Events (AEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Local and Systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Unsolicited Local and Systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Progression of DAT loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Broader Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain as measured by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stiffness of the right upper trapezius myofascial trigger point measured by MyoptronPRO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stiffness (Hz) of the right upper trapezius myofascial trigger point measured by sono-myoelastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24h) Plasma OM3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biplanar radiography and 3D reconstruction of hindfoot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech sound production accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expressive language skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Success Rate
Endpoint domain: Mortality/survival
Primary endpoint: recruitment rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: loss to follow-up and drop-out rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: adherence to study procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tumour Non-recurrence Rate
Endpoint domain: Mortality/survival
Primary endpoint: PASS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in aortic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum tolerated dose of donor NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of dulanermin
Endpoint domain: Adverse events/effects
Primary endpoint: duration of prolonged sitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of proximal tubal occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasopharyngeal carriage or Invasive Pneumococcal Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With IgG Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of circulating microemboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Resolve Air Lung Leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reperfusion treatment ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infant weight z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant skinfold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sickle cell complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Size of the thyroid tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Weekly Health Appointment Measure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: DASH Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of injured arm compared to uninjured arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Range of motion in injured arm compared to uninjured arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in First aid skills test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of models successfully undergoing drug testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIN (Chemotherapy-Induced Nausea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients eligible for PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Resting State Disorganization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in AAI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Preparation (Cleaning Rated as Good or Excellent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiotoxicity Prediction Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Troponin-T test result from baseline to 6 hours post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Troponin-T test result from 6 hours to 12 hours post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Troponin-T test result from 12 hours to 24 hours post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Troponin-T test result from 24 hours to 48 hours post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Flow Index (BFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-stent Late Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Achilles Tendon Total Rupture Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in level of fractional exhaled nitric oxide (FeNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ADHD-IV rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: side effects scale
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of epidural catheter to control pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 infection's symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive control function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Episodic memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cmax - Max plasma concentration of SENS-218
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax - Time taken to reach Cmax for SENS-218
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - area under the concentration-time curve of SENS-218
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Detoxified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter associated complications
Endpoint domain: Adverse events/effects
Primary endpoint: Progressive kidney failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Grade 3-4 diarrhea prevention
Endpoint domain: Adverse events/effects
Primary endpoint: Post Operative Wound Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in severity of obstructive sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participant Toxicity Data
Endpoint domain: Adverse events/effects
Primary endpoint: Change in hemoglobin A1c (HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of advanced glycation end products in maternal serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maintenance of healthy vaginal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood Flow Rate at First Use After Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Number of Reported Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: The Percentage of Participants With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: The Number of Episodes of Change in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self efficacy for exercise
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stage of change for exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Experience One or More Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinue Study Treatment Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: NIAPAS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability and toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary and non-coronary cardiac findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comfort Level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical healing according to presence of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the size and the PAI score of the periapical lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemagglutination inhibition (HI) antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete response rate in acute and delayed nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reach
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction with program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients That do Not Have a Failure of Technical Success or Loss of Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Serious Adverse Events (Related to Initial Procedure or the Device Itself) That Occur Within 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Change in lumbar pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disability caused by lumbar pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the functional assessment of the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of maintenance immunosuppressive drugs
Endpoint domain: Adverse events/effects
Primary endpoint: PE Sessions Attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Posttraumatic Stress Disorder (PTSD) Checklist-5
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patient Encounters That Report a New or Worsening Symptom
Endpoint domain: Adverse events/effects
Primary endpoint: Successful production of CD19-CD34 CAR product meeting release criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence-free survival at one year
Endpoint domain: Mortality/survival
Primary endpoint: Expansion of Natural Killer Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Glucose variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Glycaemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bleeds managed at home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatments resulting in the control of bleeding episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatments resulting in effective pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Response (Complete Response and Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fugl-Meyer Assessment Upper Extremity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Data completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of the recurrence of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trough concentrations of 6-TGN and 6-MMPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Drug Related Adverse Events (AEs) or Any Serious AE's
Endpoint domain: Adverse events/effects
Primary endpoint: Burden of premature ventricular complexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients With Actionable Genomic Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR unadjusted treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: PCR adjusted treatment failure up to day 28
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from pre-surgical phoria at 12 weeks post surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from pre-surgical fusional vergence at 12 weeks post surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from pre-surgical convergence amplitude at 12 weeks post surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from pre-surgical vergence facility at 12 weeks post surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from pre-surgical accommodative amplitude at 12 weeks post surgery (refractive error group only)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the Paced Auditory Serial Addition Test (PASAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in behavioral symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in repetitive behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of suboptimal care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean area under the curve (AUC) of plasma concentration vs. time of total 6-PN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum plasma concentration (Cmax) of total 6-PN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum plasma concentration (Tmax) of total 6-PN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pain score during the latent phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes